The detectability of psilocybin, the psychoactive compound in sure fungi, by normal drug screening strategies is restricted. Routine drug checks typically don’t embrace particular assays for psilocybin or its metabolite, psilocin. For instance, a normal five-panel drug take a look at screens for substances like amphetamines, cocaine, opioids, phencyclidine (PCP), and tetrahydrocannabinol (THC), none of that are associated to psilocybin.
The first cause these substances aren’t routinely screened for lies of their speedy metabolism and elimination from the physique, in addition to the comparatively excessive value and complexity of particular assays. Traditionally, drug testing panels have targeted on substances with increased charges of abuse and longer detection home windows. Moreover, psilocybin’s Schedule I classification impacts analysis and growth of available and cost-effective testing strategies.